Chemical Structure (Uptravi 01)
Uptravi Tablet, Coated
Product Images NDC 66215-604
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Uptravi (NDC 66215-604). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Actelion Pharmaceuticals Us, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Uptravi 02)
Figure 2 (Uptravi 03)
Figure 3 A (Uptravi 04)
This text contains information regarding drugs and their potential interactions. It provides a list of drugs that may interact with gemfibrozil, clopidogrel, lopinavir, rifampin, and warfarin. It also contains information on the effects of Selexipag and its active metabolite on different parameters such as AUC and Cmax. The text appears to be part of a scientific or medical study and includes fold-change estimates relative to Selexipag alone.*
Figure 3b (Uptravi 05)
Figure 3 C (Uptravi 06)
This appears to be a comparison between the drug UPTRAVI and a placebo on a group of patients over a period of 36 months. The Hazard Ratio was 0.60 with a 99% confidence interval of (0.46, 0.78) and a p-value of <0.0001. The number of patients at risk is given for each time point. No further information is available.*
Figure 4 (Uptravi 07)
Principal Display Panel (200 mcg Tablet Bottle Carton)
This appears to be a description of the results of a clinical trial testing a medication called UPTRAVI over the course of several months. The text contains a chart that shows the number of patients at risk during each month of the trial for those taking UPTRAVI and those taking a placebo.*
Principal Display Panel (400 mcg Tablet Bottle Carton)
Principal Display Panel (600 mcg Tablet Bottle Carton)
This is a table showing Hazard ratios with 99% confidence intervals for different variables such as treatment types, WHO functional class, sex, race, age, pulmonary arterial hypertension etiology, and geographical region, along with the Overall Treatment Effect. It seems to be a part of a research article aiming to evaluate the effectiveness of PAH therapy.*
Principal Display Panel (800 mcg Tablet Bottle Carton)
Principal Display Panel (1000 mcg Tablet Bottle Carton)
Uptravir is a prescription medication available in the form of 60 film-coated tablets. Each tablet contains 400 mg of selexipag, intended for oral use only. The recommended dose is advised to be taken after consulting with your doctor. The medication is stored between 15°C to 30°C (59°F and 86°F). The relevant prescribing and patient information including lot number and expiration date can be found on the bottom panel of the pack. The medication is manufactured for Actelion Pharmaceuticals US, Inc with patent information available on their website. The medication is not intended for use by children. Made in the UK, the medication is a useful treatment option after seeking medical advice.*
Principal Display Panel (1200 mcg Tablet Bottle Carton)
This is a medication with the brand name of "selexipag". Each film-coated tablet contains 600 mg of selexipag. It is manufactured by Actelion Pharmaceuticals US, Inc. and should be stored at a temperature between 15°C and 30°C (59°F and 86°F). This is only available through a prescription (Rxonly) and should be kept out of reach of children. The other information on the label seems to indicate the manufacturer, country of origin, lot number, and expiration.*
Principal Display Panel (1400 mcg Tablet Bottle Carton)
This is a description of a medication called Uptravi (selexipag) that comes in the form of 60 film-coated tablets, with each tablet containing 800 mcg of selexipag. There is NDC information, the recommended dosage and prescribing information, and storage information. The medication is manufactured by Actelion Pharmaceuticals and it is only available through a prescription. The text also includes patent and legal information, but there is no information about sofas or Bedixapes, so it is not clear how these terms relate to the medication.*
Principal Display Panel (1600 mcg Tablet Bottle Carton)
Uptravi is a medication that comes in film-coated tablets. Each tablet contains 1000 mcg of selexipag. It is a prescription medication that should only be used after reading the prescribing and patient information. The recommended dosage can be found in the prescribing information. It should be kept out of reach of children. See the bottom panel for the lot number and expiration date. Made in the UK by Actlion Pharmaceuticals US, Inc.*
Principal Display Panel (Kit Carton)
This is a description of a medication named Uptravi (selexipag). Each film-coated tablet contains 1200 mcg of the active ingredient. The recommended dosage should be read in the Prescribing Information. These are prescription-only tablets and should be stored at controlled room temperature of 20-25°C. The medication is manufactured for Actelion Pharmaceuticals US, Inc. and made in the UK. The lot number and expiration date can be found on the bottom panel.*
Uptravi 17
Uptravi 18
Uptravi 19
Uptravi is a medication available in film-coated tablets of two strengths, 800 mcg and 200 mg, sold in bottles of 60 and 140 tablets. The tablets contain Selexipag as its active ingredient. The recommended dosage is mentioned in the prescribing information. The medication should be stored at a temperature ranging from 20°C to 25°C, with permissible excursions between 15°C and 30°C. Uptravi is a prescription-only medication and should be used after reading the prescribing and patient information. Manufacturing of the medication is done in the UK. Lot number and expiration date details are available on the packaging.*
Uptravi 20
This appears to be a label for a medication called Uptravi, which comes in a single-use vial that contains 1,800 micrograms of selexipag and other inactive ingredients. The vial should be reconstituted and diluted before use and any unused portion should be discarded. The label also includes instructions for administering the medication via intravenous infusion. There is also a warning on the label to open the vial from the bottom and to keep it in the original carton to protect it. The NDC code for this medication is 66215-718-01.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
